Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 142 articles:
HTML format



Single Articles


    July 2022
  1. DERLIN T, Widjaja L, Werner RA, Bengel FM, et al
    (177)Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022 Jul 19. pii: jnumed.122.264293. doi: 10.2967/jnumed.122.264293.
    PubMed     Abstract available


  2. KOEHLER D, Sauer M, Klutmann S, Apostolova I, et al
    Feasibility of (99m)Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients.
    J Nucl Med. 2022 Jul 14. pii: jnumed.122.263892. doi: 10.2967/jnumed.122.263892.
    PubMed     Abstract available


  3. HOFLING AA, Fotenos AF, Niu G, Fallah J, et al
    Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.
    J Nucl Med. 2022 Jul 7. pii: jnumed.122.264299. doi: 10.2967/jnumed.122.264299.
    PubMed    


  4. PAINDELLI C, Casarin S, Wang F, Diaz-Gomez L, et al
    Enhancing (223)Ra Treatment Efficacy by Anti-beta1 Integrin Targeting.
    J Nucl Med. 2022;63:1039-1045.
    PubMed     Abstract available


    June 2022
  5. PATHMANANDAVEL S, Crumbaker M, Nguyen A, Yam AOW, et al
    The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with (177)LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
    J Nucl Med. 2022 Jun 23. pii: jnumed.122.264104. doi: 10.2967/jnumed.122.264104.
    PubMed     Abstract available


  6. SIEBINGA H, Olde Heuvel J, Rijkhorst EJ, Hendrikx JJMA, et al
    The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on (68)Ga-PSMA-11 PET/CT in Primary Prostate Cancer Patients.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264101. doi: 10.2967/jnumed.122.264101.
    PubMed     Abstract available


  7. POMYKALA KL, Herrmann K, Padhani AR, Hofman MS, et al
    Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Prostate Cancer: We have the answers.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264394. doi: 10.2967/jnumed.122.264394.
    PubMed    


  8. SARTOR O, Herrmann K
    Prostate Cancer Treatment: (177)Lu-PSMA-617 Considerations, Concepts, and Limitations.
    J Nucl Med. 2022;63:823-829.
    PubMed     Abstract available


  9. JADVAR H
    The VISION Forward: Recognition and Implication of PSMA-/(18)F-FDG+ mCRPC.
    J Nucl Med. 2022;63:812-815.
    PubMed     Abstract available


    May 2022
  10. DUAN H, Baratto L, Fan RE, Soerensen SJC, et al
    Correlation of (68)Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
    J Nucl Med. 2022 May 12. pii: jnumed.122.263971. doi: 10.2967/jnumed.122.263971.
    PubMed     Abstract available



  11. FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022;63:13N.
    PubMed    


    April 2022
  12. DENIS CES, Cousin FC, De Laere B, Hustinx R, et al
    Using, (68)Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
    J Nucl Med. 2022 Apr 21. pii: jnumed.121.263611. doi: 10.2967/jnumed.121.263611.
    PubMed     Abstract available


  13. GAFITA A, Rauscher I, Weber M, Hadaschik B, et al
    Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
    J Nucl Med. 2022 Apr 14. pii: jnumed.121.263072. doi: 10.2967/jnumed.121.263072.
    PubMed     Abstract available


  14. KROENKE M, Schweiger L, Horn T, Haller B, et al
    Validation of (18)F-rhPSMA-7 and (18)F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
    J Nucl Med. 2022 Apr 7. pii: jnumed.121.263707. doi: 10.2967/jnumed.121.263707.
    PubMed     Abstract available


    March 2022
  15. EMMETT LM, Papa N, Buteau J, Ho B, et al
    The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.
    J Nucl Med. 2022 Mar 17. pii: jnumed.121.263448. doi: 10.2967/jnumed.121.263448.
    PubMed     Abstract available


  16. ILHAN H, Kroenke M, Wurzer A, Unterrainer M, et al
    (18)F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.262861. doi: 10.2967/jnumed.121.262861.
    PubMed     Abstract available


  17. NOTOHAMIPRODJO S, Eiber M, Lohrmann C, Weber WA, et al
    Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on (18)F-rhPSMA-7.3 PET/CT in patients with prostate cancer.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263758. doi: 10.2967/jnumed.121.263758.
    PubMed     Abstract available


  18. GONDOPUTRO W, Scheltema MJ, Blazevski A, Doan P, et al
    Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263743. doi: 10.2967/jnumed.121.263743.
    PubMed     Abstract available


    February 2022
  19. WU WY, Yu F, Zhang PJ, Bu T, et al
    (68)Ga-DOTA-NT-20.3 Neurotensin receptor 1 positron emission tomography imaging as a surrogate for neuroendocrine differentiation of prostate cancer.
    J Nucl Med. 2022 Feb 17. pii: jnumed.121.263132. doi: 10.2967/jnumed.121.263132.
    PubMed     Abstract available



  20. FDA Approves New (68)Ga Kit for Prostate Cancer PET.
    J Nucl Med. 2022;63:26N.
    PubMed    


  21. SARTOR O
    Reply: A VISION of ALSYMPCA.
    J Nucl Med. 2022;63:324-325.
    PubMed    


  22. SCHIAVOM DUARTE P
    A VISION of ALSYMPCA.
    J Nucl Med. 2022;63:324.
    PubMed    


  23. MEASE RC, Kang CM, Kumar V, Banerjee SR, et al
    An Improved (211)At-Labeled Agent for PSMA-Targeted alpha-Therapy.
    J Nucl Med. 2022;63:259-267.
    PubMed     Abstract available


    January 2022
  24. WURZER A, Kunert JP, Fischer S, Felber V, et al
    Synthesis and Preclinical Evaluation of (177)Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.263371. doi: 10.2967/jnumed.121.263371.
    PubMed     Abstract available


  25. KORSEN JA, Kalidindi TM, Khitrov S, Samuels ZV, et al
    Molecular imaging of Neuroendocrine Prostate Cancer by targeting Delta-like Ligand 3.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263221. doi: 10.2967/jnumed.121.263221.
    PubMed     Abstract available


  26. SUTERA P, Phillips RM, Deek M, Ozyigit G, et al
    The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer - Going Beneath the Surface with Molecular Imaging.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263684. doi: 10.2967/jnumed.121.263684.
    PubMed    


  27. LANGBEIN T, Wang H, Rauscher I, Kronke M, et al
    Utility of (18)F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
    J Nucl Med. 2022 Jan 6. pii: jnumed.121.263440. doi: 10.2967/jnumed.121.263440.
    PubMed     Abstract available


  28. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The Added Value of (18)F-FDG PET/CT Compared with (68)Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022;63:69-75.
    PubMed     Abstract available


    December 2021
  29. MENA E, Rowe SP, Shih JH, Lindenberg L, et al
    Predictors of (18)F-DCFPyL-PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.
    J Nucl Med. 2021 Dec 16. pii: jnumed.121.262347. doi: 10.2967/jnumed.121.262347.
    PubMed     Abstract available


  30. SCHUCHARDT C, Zhang J, Kulkarni HR, Chen X, et al
    Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.262713. doi: 10.2967/jnumed.121.262713.
    PubMed     Abstract available


    November 2021
  31. SHAGERA QA, Artigas C, Karfis I, Critchi G, et al
    (68)Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.263006. doi: 10.2967/jnumed.121.263006.
    PubMed     Abstract available


  32. CALAIS J, Czernin J
    PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
    J Nucl Med. 2021;62:1489-1491.
    PubMed    


  33. SRINIVAS S, Iagaru A
    To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.
    J Nucl Med. 2021;62:1487-1488.
    PubMed    


    October 2021
  34. MIYAHIRA AK, Soule HR
    The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Foundational Role of the Prostate Cancer Foundation.
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.262997. doi: 10.2967/jnumed.121.262997.
    PubMed     Abstract available


  35. SONNI I, Felker ER, Lenis AT, Sisk AE, et al
    Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial.
    J Nucl Med. 2021 Oct 14. pii: jnumed.121.262398. doi: 10.2967/jnumed.121.262398.
    PubMed     Abstract available


  36. CALAIS J, Czernin J, Thin P, Gartmann J, et al
    Safety of PSMA-Targeted Molecular Radioligand Therapy with (177)Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
    J Nucl Med. 2021;62:1447-1456.
    PubMed     Abstract available


  37. NOTNI J
    PSMA-Targeted Therapeutics: A Tale About Law and Economics.
    J Nucl Med. 2021;62:1482.
    PubMed    


  38. EDER AC, Schafer M, Schmidt J, Bauder-Wust U, et al
    Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules.
    J Nucl Med. 2021;62:1461-1467.
    PubMed     Abstract available


    September 2021
  39. FEUERECKER B, Chantadisai M, Allmann A, Tauber R, et al
    Pre-therapeutic comparative dosimetry of (177)Lu-rhPSMA-7.3 and (177)Lu-PSMAI&T in patients with metastatic castration resistant prostate cancer (mCRPC).
    J Nucl Med. 2021 Sep 16. pii: jnumed.121.262671. doi: 10.2967/jnumed.121.262671.
    PubMed     Abstract available


  40. LEE DY, Kim YI
    Effects of (225)Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: A meta-analysis.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262017. doi: 10.2967/jnumed.121.262017.
    PubMed     Abstract available


  41. FOURQUET A, Rosenberg A, Mena E, Shih JJ, et al
    A comparison of (18)F-DCFPyL, (18)F-NaF and (18)F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer.
    J Nucl Med. 2021 Sep 2. pii: jnumed.121.262371. doi: 10.2967/jnumed.121.262371.
    PubMed     Abstract available


  42. WAHL RL
    Progress in Prostate Cancer Theranostics.
    J Nucl Med. 2021;62:11N.
    PubMed    


  43. BRENNER W, Strobel J, Prasad V
    PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?
    J Nucl Med. 2021;62:1242-1243.
    PubMed    


    August 2021
  44. SEIFERT R, Sandach P, Kersting D, Fendler WP, et al
    Repeatability of (68)Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
    J Nucl Med. 2021 Aug 26. pii: jnumed.121.262528. doi: 10.2967/jnumed.121.262528.
    PubMed     Abstract available


  45. PARIHAR AS, Schmidt LR, Dehdashti F, Wahl RL, et al
    Detection of additional primary neoplasms on (18)F-Fluciclovine PET/CT in patients with primary prostate cancer.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262647. doi: 10.2967/jnumed.121.262647.
    PubMed     Abstract available


  46. SANDHU S, Guo C, Hofman MS
    Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
    J Nucl Med. 2021 Aug 12. pii: jnumed.120.243295. doi: 10.2967/jnumed.120.243295.
    PubMed     Abstract available


  47. LANGBEIN T, Wurzer A, Gafita A, Robertson A, et al
    The Influence of Specific Activity on the Biodistribution of (18)F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262471. doi: 10.2967/jnumed.121.262471.
    PubMed     Abstract available



  48. FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.
    PubMed    



  49. FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.
    PubMed    


  50. CZERNIN J, Calais J
    (177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
    J Nucl Med. 2021;62:1025-1026.
    PubMed    


  51. YUSUFI N, Wurzer A, Herz M, D'Alessandria C, et al
    Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using (19)F/(177)Lu-rhPSMA-7.3 and (177)Lu-PSMA I&T.
    J Nucl Med. 2021;62:1106-1111.
    PubMed     Abstract available


  52. FERNANDEZ R, Eppard E, Lehnert W, Jimenez-Franco LD, et al
    Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases.
    J Nucl Med. 2021;62:1126-1132.
    PubMed     Abstract available


  53. URBAN S, Meyer C, Dahlbom M, Farkas I, et al
    Radiation Dosimetry of (99m)Tc-PSMA I&S: A Single-Center Prospective Study.
    J Nucl Med. 2021;62:1075-1081.
    PubMed     Abstract available


    July 2021
  54. DIETLEIN F, Kobe C, Munoz Vazquez S, Fischer T, et al
    An (89)Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262290. doi: 10.2967/jnumed.121.262290.
    PubMed     Abstract available


  55. DONG L, Su Y, Zhu Y, Markowski MC, et al
    The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262411. doi: 10.2967/jnumed.121.262411.
    PubMed     Abstract available


  56. PATHMANANDAVEL S, Crumbaker M, Yam AO, Nguyen A, et al
    (177)Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262552. doi: 10.2967/jnumed.121.262552.
    PubMed     Abstract available


  57. ABGHARI-GERST M, Armstrong WR, Nguyen K, Calais J, et al
    A comprehensive assessment of (68)Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262412. doi: 10.2967/jnumed.121.262412.
    PubMed     Abstract available


  58. BENARD F, Bratanovic IJ
    A Novel Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor Positive Prostate Cancer.
    J Nucl Med. 2021 Jul 22. pii: jnumed.120.257758. doi: 10.2967/jnumed.120.257758.
    PubMed     Abstract available


  59. CERCI JJ, Fanti S, Lobato EE, Kunikowska J, et al
    Diagnostic performance and clinical impact of (68)Ga-PSMA-11 imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study).
    J Nucl Med. 2021 Jul 2. pii: jnumed.120.261886. doi: 10.2967/jnumed.120.261886.
    PubMed     Abstract available


    June 2021
  60. SARTOR AO, la Fougere C, Essler M, Ezziddin S, et al
    Lutetium-177-prostate-specific membrane antigen ligand following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience.
    J Nucl Med. 2021 Jun 24. pii: jnumed.121.262240. doi: 10.2967/jnumed.121.262240.
    PubMed     Abstract available


  61. MIX M, Renaud T, Kind F, Nemer U, et al
    Kidney doses in (177)Lu-based radioligand therapy in prostate cancer: Is dose estimation based on reduced dosimetry measurements feasible?
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262245. doi: 10.2967/jnumed.121.262245.
    PubMed     Abstract available


  62. MCINNES LE, Cullinane C, Roselt PD, Jackson S, et al
    Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with (67)Cu.
    J Nucl Med. 2021;62:829-832.
    PubMed     Abstract available


    May 2021
  63. NICKOLS N, Anand A, Johnsson K, Brynolfsson J, et al
    aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL (PSMA) images of Veterans with Prostate Cancer.
    J Nucl Med. 2021 May 28. pii: jnumed.120.261863. doi: 10.2967/jnumed.120.261863.
    PubMed     Abstract available


  64. GAFITA A, Wang H, Robertson A, Armstrong WR, et al
    Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or Reality?
    J Nucl Med. 2021 May 28. pii: jnumed.121.261906. doi: 10.2967/jnumed.121.261906.
    PubMed     Abstract available


  65. CALAIS J, Gafita A, Eiber MR, Armstrong WR, et al
    Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.
    J Nucl Med. 2021 May 20. pii: jnumed.121.261982. doi: 10.2967/jnumed.121.261982.
    PubMed     Abstract available


  66. BARBATO F, Fendler WP, Rauscher I, Herrmann K, et al
    PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
    J Nucl Med. 2021 May 14. pii: jnumed.121.262120. doi: 10.2967/jnumed.121.262120.
    PubMed     Abstract available


  67. TREIBER H, Koenig A, Neesse A, Richter A, et al
    Liver enzyme elevation after (177)Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer.
    J Nucl Med. 2021 May 14. pii: jnumed.120.258533. doi: 10.2967/jnumed.120.258533.
    PubMed     Abstract available


  68. ZACHERL MJ, Gildehaus FJ, Mittlmeier L, Boning G, et al
    First Clinical Results for PSMA-Targeted alpha-Therapy Using (225)Ac-PSMA-I&T in Advanced-mCRPC Patients.
    J Nucl Med. 2021;62:669-674.
    PubMed     Abstract available


    April 2021
  69. FENDLER WP, Farolfi A
    REPLY: The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
    J Nucl Med. 2021 Apr 30. pii: jnumed.121.262271. doi: 10.2967/jnumed.121.262271.
    PubMed    


  70. OLDE HEUVEL J, de Wit-van der Veen BJ, van der Poel HG, van Leeuwen PJ, et al
    Cerenkov Luminescence Imaging in prostate cancer: not the only light that shines.
    J Nucl Med. 2021 Apr 30. pii: jnumed.120.260034. doi: 10.2967/jnumed.120.260034.
    PubMed     Abstract available


  71. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The added value of (18)F-FDG PET/CT compared to (68)Ga-PSMA PET/CT in patients with castration-resistant prostate cancer.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262250. doi: 10.2967/jnumed.121.262250.
    PubMed     Abstract available


  72. BRAVI CA, Fossati N, Gandaglia G, Suardi N, et al
    The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
    J Nucl Med. 2021 Apr 16. pii: jnumed.121.262104. doi: 10.2967/jnumed.121.262104.
    PubMed    


    March 2021
  73. BAKKER IL, Froberg AC, Busstra MB, Verzijlbergen JF, et al
    GRPr antagonist (68)Ga-SB3 PET/CT-imaging of primary prostate cancer in therapy-naive patients.
    J Nucl Med. 2021 Mar 31. pii: jnumed.120.258814. doi: 10.2967/jnumed.120.258814.
    PubMed     Abstract available


  74. TRAGARDH E, Simoulis A, Bjartell A, Jogi J, et al
    Tumor detection of (18)F-PSMA-1007 in the prostate gland in patients with prostate cancer using prostatectomy specimens as reference method.
    J Nucl Med. 2021 Mar 31. pii: jnumed.121.261993. doi: 10.2967/jnumed.121.261993.
    PubMed     Abstract available


  75. AFAQ A, Payne H, Davda R, Hines J, et al
    A Phase II, Open-label study to assess safety and management change using (68)Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED study.
    J Nucl Med. 2021 Mar 19. pii: jnumed.120.257527. doi: 10.2967/jnumed.120.257527.
    PubMed     Abstract available


  76. BUCKNOR MD, Hope T
    Reply: "Disparities in PET imaging for prostate cancer at a tertiary academic medical center".
    J Nucl Med. 2021 Mar 19. pii: jnumed.121.262332. doi: 10.2967/jnumed.121.262332.
    PubMed    


  77. FAROLFI A, Calderoni L, Mattana F, Mei R, et al
    Current and emerging clinical applications of PSMA-PET diagnostic imaging for prostate cancer.
    J Nucl Med. 2021 Mar 12. pii: jnumed.120.257238. doi: 10.2967/jnumed.120.257238.
    PubMed     Abstract available


  78. UPRIMNY C, Bayerschmidt S, Kroiss AS, Fritz J, et al
    Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for (68)Ga-PSMA-11 PET/CT.
    J Nucl Med. 2021 Mar 12. pii: jnumed.120.261866. doi: 10.2967/jnumed.120.261866.
    PubMed     Abstract available


  79. RAUSCHER I, Karimzadeh A, Schiller K, Horn T, et al
    Detection efficacy of (18)F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
    J Nucl Med. 2021 Mar 12. pii: jnumed.120.260091. doi: 10.2967/jnumed.120.260091.
    PubMed     Abstract available


  80. BARATTO L, Song H, Duan H, Hatami N, et al
    PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
    J Nucl Med. 2021 Mar 5. pii: jnumed.120.259630. doi: 10.2967/jnumed.120.259630.
    PubMed     Abstract available


  81. RITT P, Jobic C, Beck M, Schmidkonz C, et al
    Dissimilar DNA Damage to Blood Lymphocytes After (177)Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2021;62:379-385.
    PubMed     Abstract available


    February 2021
  82. SUH M, Im HJ, Ryoo HG, Kang KW, et al
    Head to head comparison of (68)Ga-NGUL and (68)Ga-PSMA-11 in patients with metastatic prostate cancer: a prospective study.
    J Nucl Med. 2021 Feb 26. pii: jnumed.120.258434. doi: 10.2967/jnumed.120.258434.
    PubMed     Abstract available


  83. ZUKOTYNSKI KA, Emmenegger U, Hotte S, Kapoor A, et al
    Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted (18)F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.
    J Nucl Med. 2021 Feb 19. pii: jnumed.120.259069. doi: 10.2967/jnumed.120.259069.
    PubMed     Abstract available


  84. WONDERGEM M, van der Zant FM, Broos WA, Knol RJ, et al
    Matched-pair comparison of (18)F-DCFPyL PET/CT and (18)F-PSMA-1007 PET/CT in 240 prostate cancer patients; inter-reader agreement and lesion detection rate of suspected lesions.
    J Nucl Med. 2021 Feb 5. pii: jnumed.120.258574. doi: 10.2967/jnumed.120.258574.
    PubMed     Abstract available


  85. MAZZONE E, Dell'Oglio P, Grivas N, Wit E, et al
    Diagnostic Value, Oncological Outcomes And Safety Profile Of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy For Prostate Cancer.
    J Nucl Med. 2021 Feb 5. pii: jnumed.120.259788. doi: 10.2967/jnumed.120.259788.
    PubMed     Abstract available


    January 2021
  86. SCHILHAM MG, Zamecnik P, Prive BM, Israel B, et al
    Head-to-head comparison of (68)Ga-prostate-specific membrane antigen PET/CT and ferumoxtran-10 enhanced MRI for the diagnosis of lymph node metastases in prostate cancer patients.
    J Nucl Med. 2021 Jan 30. pii: jnumed.120.258541. doi: 10.2967/jnumed.120.258541.
    PubMed     Abstract available


  87. ABIODUN-OJO OA, Jani AB, Akintayo AA, Akin-Akintayo OO, et al
    Salvage Radiotherapy Management Decision in Post-prostatectomy Patients with Recurrent Prostate Cancer Based on (18)F-Fluciclovine PET/CT Guidance.
    J Nucl Med. 2021 Jan 30. pii: jnumed.120.256784. doi: 10.2967/jnumed.120.256784.
    PubMed     Abstract available


  88. ARMSTRONG WR, Gafita A, Zhu S, Thin P, et al
    The impact of monosodium glutamate on (68)Ga-PSMA-11 biodistribution in men with prostate cancer: a prospective randomized, controlled, imaging study.
    J Nucl Med. 2021 Jan 28. pii: jnumed.120.257931. doi: 10.2967/jnumed.120.257931.
    PubMed     Abstract available


  89. BODAR YJL, Koene BPF, Jansen BHE, Cysouw MCF, et al
    Standardized Uptake Values are Adequate Measures of Lesional (18)F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
    J Nucl Med. 2021 Jan 28. pii: jnumed.120.260232. doi: 10.2967/jnumed.120.260232.
    PubMed     Abstract available


  90. MARKOWSKI MC, Velho PI, Eisenberger MA, Pomper MG, et al
    Detection of Early Progression with (18)F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.
    J Nucl Med. 2021 Jan 15. pii: jnumed.120.259226. doi: 10.2967/jnumed.120.259226.
    PubMed     Abstract available


  91. WIBMER AG, Morris MJ, Gonen M, Zheng J, et al
    QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE- CENTER RETROSPECTIVE COHORT STUDY.
    J Nucl Med. 2021 Jan 8. pii: jnumed.120.256602. doi: 10.2967/jnumed.120.256602.
    PubMed     Abstract available


    December 2020
  92. KROENKE M, Mirzoyan L, Horn T, Peeken JC, et al
    Matched-pair comparison of (68)Ga-PSMA-11 and (18)F-rhPSMA-7 PET/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor related uptake and tumor positivity.
    J Nucl Med. 2020 Dec 4. pii: jnumed.120.251447. doi: 10.2967/jnumed.120.251447.
    PubMed     Abstract available


  93. STUPARU AD, Capri JR, Meyer C, Le TM, et al
    Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.
    J Nucl Med. 2020 Dec 4. pii: jnumed.120.256263. doi: 10.2967/jnumed.120.256263.
    PubMed     Abstract available


  94. HOFMAN MS
    Prostate-Specific Membrane Antigen: The Target of the Decade, from Biochemical Recurrence to Widespread Adoption.
    J Nucl Med. 2020;61.
    PubMed    


    November 2020
  95. RAY S, Lisok A, Minn IL, Josefsson A, et al
    Preclinical evaluation of (213)Bi-/(225)Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer.
    J Nucl Med. 2020 Nov 27. pii: jnumed.120.256388. doi: 10.2967/jnumed.120.256388.
    PubMed     Abstract available


  96. CHANTADISAI M, Buschner G, Kronke M, Rauscher I, et al
    Positive predictive value and correct detection rate of (18)F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard.
    J Nucl Med. 2020 Nov 13. pii: jnumed.120.255661. doi: 10.2967/jnumed.120.255661.
    PubMed     Abstract available


  97. MEIJER D, Donswijk ML, Bodar YJL, van Leeuwen PJ, et al
    Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging.
    J Nucl Med. 2020 Nov 6. pii: jnumed.120.252528. doi: 10.2967/jnumed.120.252528.
    PubMed     Abstract available


    October 2020
  98. KOSTYSZYN D, Fechter T, Bartl N, Grosu AL, et al
    Intraprostatic Tumour Segmentation on PSMA-PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network.
    J Nucl Med. 2020 Oct 30. pii: jnumed.120.254623. doi: 10.2967/jnumed.120.254623.
    PubMed     Abstract available


  99. FRANC BL, Iagaru A
    Letter to the Editor: "Disparities in PET imaging for prostate cancer at a tertiary academic medical center".
    J Nucl Med. 2020 Oct 30. pii: jnumed.120.258160. doi: 10.2967/jnumed.120.258160.
    PubMed    


  100. LODGE MA, Lesniak W, Gorin MA, Pienta KJ, et al
    Measurement of PET Quantitative Bias In Vivo.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.251397. doi: 10.2967/jnumed.120.251397.
    PubMed     Abstract available


  101. DARR C, Harke NN, Radtke JP, Yirga L, et al
    Intraoperative (68)Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility Study.
    J Nucl Med. 2020;61:1500-1506.
    PubMed     Abstract available


    September 2020
  102. BUCKNOR MD, Lichtensztajn DY, Lin TK, Borno HT, et al
    Disparities in PET imaging for prostate cancer at a tertiary academic medical center.
    J Nucl Med. 2020 Sep 25. pii: jnumed.120.251751. doi: 10.2967/jnumed.120.251751.
    PubMed     Abstract available


  103. FAROLFI A, Hirmas N, Gafita A, Weber M, et al
    PSMA-PET identifies PCWG3 target populations with superior accuracy and reproducibility when compared to conventional imaging: a multicenter retrospective study.
    J Nucl Med. 2020 Sep 11. pii: jnumed.120.246603. doi: 10.2967/jnumed.120.246603.
    PubMed     Abstract available


  104. LI YR, Roach M 3rd
    The Roach Equation: Value of Old Clinical Tools in the Era of New Molecular Imaging.
    J Nucl Med. 2020;61:1292-1293.
    PubMed    


    August 2020
  105. SPRUTE K, Kramer V, Koerber S, Meneses M, et al
    Diagnostic accuracy of (18)F-PSMA-1007-PET/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence.
    J Nucl Med. 2020 Aug 17. pii: jnumed.120.246363. doi: 10.2967/jnumed.120.246363.
    PubMed     Abstract available


  106. FOSBOL MO, Kurbegovic S, Johannesen HH, Roder MA, et al
    Urokinase Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Non-invasive Evaluation of Aggressiveness: a Prospective Phase II Clinical Trial Comparing with Gleason Score.
    J Nucl Med. 2020 Aug 6. pii: jnumed.120.248120. doi: 10.2967/jnumed.120.248120.
    PubMed     Abstract available


  107. POLLARD JH, Raman C, Zakharia Y, Tracy CR, et al
    Quantitative Test-Retest Measurement of (68)Ga-PSMA-HBED-CC in Tumor and Normal Tissue.
    J Nucl Med. 2020;61:1145-1152.
    PubMed     Abstract available


    July 2020
  108. CZERNIN J, Current K, Mona CE, Nyiranshuti L, et al
    Immune-Checkpoint Blockade Enhances (225)Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer.
    J Nucl Med. 2020 Jul 9. pii: jnumed.120.246041. doi: 10.2967/jnumed.120.246041.
    PubMed     Abstract available


    June 2020
  109. SOULE HR, Czernin J
    A Conversation Between Howard Soule and Johannes Czernin.
    J Nucl Med. 2020;61:774-776.
    PubMed    


  110. CZERNIN J
    Two Leaders.
    J Nucl Med. 2020;61:773.
    PubMed    


  111. BARATTO L, Duan H, Macke H, Iagaru A, et al
    Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer.
    J Nucl Med. 2020;61:792-798.
    PubMed     Abstract available


    May 2020
  112. WEBER M, Kurek CE, Barbato F, Eiber M, et al
    PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study.
    J Nucl Med. 2020 May 22. pii: jnumed.120.245456. doi: 10.2967/jnumed.120.245456.
    PubMed     Abstract available


  113. KLINGENBERG S, Jochumsen MR, Ulhoi BP, Fredsoe J, et al
    (68)Ga-PSMA PET/CT for primary NM staging of high-risk prostate cancer.
    J Nucl Med. 2020 May 22. pii: jnumed.120.245605. doi: 10.2967/jnumed.120.245605.
    PubMed     Abstract available


  114. DITTMANN H, Kaltenbach S, Weissinger M, Fiz F, et al
    The prognostic value of quantitative bone scan SPECT/CT prior to (223)Ra treatment in metastatic castration-resistant prostate cancer (mCRPC).
    J Nucl Med. 2020 May 22. pii: jnumed.119.240408. doi: 10.2967/jnumed.119.240408.
    PubMed     Abstract available


  115. HARSINI S, Saprunoff H, Alden TM, Mohammadi B, et al
    The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.
    J Nucl Med. 2020 May 8. pii: jnumed.120.246983. doi: 10.2967/jnumed.120.246983.
    PubMed     Abstract available


  116. FENDLER WP, Ferdinandus J, Czernin J, Eiber M, et al
    Impact of (68)Ga-PSMA-11 PET on the Management of recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial.
    J Nucl Med. 2020 May 1. pii: jnumed.120.242180. doi: 10.2967/jnumed.120.242180.
    PubMed     Abstract available


  117. ZANG J, Liu Q, Sui H, Wang R, et al
    (177)Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2020 May 1. pii: jnumed.120.242263. doi: 10.2967/jnumed.120.242263.
    PubMed     Abstract available


  118. RATHKE H, Holland-Letz T, Mier W, Flechsig P, et al
    Response Prediction of (177)Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase.
    J Nucl Med. 2020;61:689-695.
    PubMed     Abstract available


  119. SEIFERT R, Kessel K, Boegemann M, Kohler M, et al
    Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy.
    J Nucl Med. 2020;61:723-728.
    PubMed     Abstract available


  120. KRATOCHWIL C, Giesel FL, Heussel CP, Kazdal D, et al
    Patients Resistant Against PSMA-Targeting alpha-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes.
    J Nucl Med. 2020;61:683-688.
    PubMed     Abstract available


    April 2020
  121. SEIFERT R, Herrmann K, Kleesiek J, Schafers MA, et al
    Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer.
    J Nucl Med. 2020 Apr 24. pii: jnumed.120.242057. doi: 10.2967/jnumed.120.242057.
    PubMed     Abstract available


  122. CHIU LW, Lawhn-Heath C, Behr S, Juarez R, et al
    Factors predicting metastatic disease in (68)Ga-PSMA-11 PET positive osseous lesions in prostate cancer.
    J Nucl Med. 2020 Apr 17. pii: jnumed.119.241174. doi: 10.2967/jnumed.119.241174.
    PubMed     Abstract available


  123. JADVAR H, Ballas LK, Choyke PL, Fanti S, et al
    Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment.
    J Nucl Med. 2020;61:552-562.
    PubMed    


    January 2020
  124. POMPER MG, Choyke PL
    Discussions with Leaders: A Conversation Between Martin Pomper and Peter Choyke.
    J Nucl Med. 2020;61:3-5.
    PubMed    


  125. MAURER T, Graefen M, van der Poel H, Hamdy F, et al
    Prostate-Specific Membrane Antigen-Guided Surgery.
    J Nucl Med. 2020;61:6-12.
    PubMed     Abstract available


  126. CARLOS DOS SANTOS J, Beijer B, Bauder-Wust U, Schafer M, et al
    Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
    J Nucl Med. 2020;61:70-79.
    PubMed     Abstract available


    December 2019
  127. FANTI S, Hadaschik B, Herrmann K
    Proposal of Systemic Therapy Response Assessment Criteria in time of PSMA PET/CT imaging: PSMA PET Progression (PPP).
    J Nucl Med. 2019 Dec 5. pii: jnumed.119.233817. doi: 10.2967/jnumed.119.233817.
    PubMed     Abstract available


  128. JACKSON PA, Hofman MS, Hicks RJ, Scalzo M, et al
    Radiation Dosimetry in (177)Lu-PSMA-617 Therapy Using a Single Post-treatment SPECT/CT: A Novel Methodology to Generate Time- and Tissue-specific Dose Factors.
    J Nucl Med. 2019 Dec 5. pii: jnumed.119.233411. doi: 10.2967/jnumed.119.233411.
    PubMed     Abstract available


    November 2019
  129. EMMETT L, Tang R, Nandurkar RH, Hruby G, et al
    3-year freedom from progression following (68)GaPSMA PET CT triaged management in men with biochemical recurrence post radical prostatectomy. Results of a prospective multi-center trial.
    J Nucl Med. 2019 Nov 1. pii: jnumed.119.235028. doi: 10.2967/jnumed.119.235028.
    PubMed     Abstract available


    October 2019
  130. CALDERONI L, Farolfi A, Pianori D, Maietti E, et al
    Automated synthesis module and sterile cold kit for (68)Ga-PSMA-11 do not show differences in PET/CT image quality.
    J Nucl Med. 2019 Oct 10. pii: jnumed.119.231605. doi: 10.2967/jnumed.119.231605.
    PubMed     Abstract available


    September 2019
  131. TORIIHARA A, Nobashi T, Baratto L, Duan H, et al
    Comparison of three interpretation criteria of (68)Ga-PSMA11 PET based on inter- and intra-reader agreement.
    J Nucl Med. 2019 Sep 27. pii: jnumed.119.232504. doi: 10.2967/jnumed.119.232504.
    PubMed     Abstract available


    July 2019
  132. LUTJE S, Franssen GM, Herrmann K, Boerman OC, et al
    In Vitro and In Vivo Characterization of an (18)F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts.
    J Nucl Med. 2019;60:1017-1022.
    PubMed     Abstract available


    June 2019
  133. RAUSCHER I, Kronke M, Konig M, Gafita A, et al
    Matched-pair comparison of (68)Ga-PSMA-11 and (18)F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy.
    J Nucl Med. 2019 Jun 28. pii: jnumed.119.229187. doi: 10.2967/jnumed.119.229187.
    PubMed     Abstract available


  134. GAMBHIR SS, Shankar LK, Rosenthal E, Warram JM, et al
    Proceedings: Pathways for Successful Translation of New Imaging Agents and Modalities-Phase III Studies.
    J Nucl Med. 2019;60:736-744.
    PubMed    


  135. EMMETT L, Metser U, Bauman G, Hicks RJ, et al
    Prospective, Multisite, International Comparison of (18)F-Fluoromethylcholine PET/CT, Multiparametric MRI, and (68)Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and P
    J Nucl Med. 2019;60:794-800.
    PubMed     Abstract available


  136. RATHKE H, Flechsig P, Mier W, Bronzel M, et al
    Dosimetry Estimate and Initial Clinical Experience with (90)Y-PSMA-617.
    J Nucl Med. 2019;60:806-811.
    PubMed     Abstract available


    May 2019
  137. KELLY JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, et al
    Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
    J Nucl Med. 2019;60:656-663.
    PubMed     Abstract available


  138. GAFITA A, Rauscher I, Retz M, Knorr K, et al
    Early Experience of Rechallenge (177)Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer.
    J Nucl Med. 2019;60:644-648.
    PubMed     Abstract available


  139. KELLY JM, Amor-Coarasa A, Ponnala S, Nikolopoulou A, et al
    A Single Dose of (225)Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model.
    J Nucl Med. 2019;60:649-655.
    PubMed     Abstract available


    April 2019
  140. LINDEMANN ME, Guberina N, Wetter A, Fendler W, et al
    Improving 68-Ga-PSMA PET/MR hybrid imaging of the prostate with un-renormalized absolute scatter correction.
    J Nucl Med. 2019 Apr 12. pii: jnumed.118.224139. doi: 10.2967/jnumed.118.224139.
    PubMed     Abstract available


    March 2019
  141. METSER U, Chua SS, Ho B, Punwani S, et al
    The contribution of multiparametric pelvic & whole body MR to interpretation of (18)F-fluoromethylcholine or (68)Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure following radical prostatectomy.
    J Nucl Med. 2019 Mar 22. pii: jnumed.118.225185. doi: 10.2967/jnumed.118.225185.
    PubMed     Abstract available


    November 2018
  142. ZLATOPOLSKIY BD, Endepols H, Krapf P, Guliyev M, et al
    Discovery of (18)F-JK-PSMA-7, a novel PET-probe for the detection of small PSMA positive lesions.
    J Nucl Med. 2018 Nov 2. pii: jnumed.118.218495. doi: 10.2967/jnumed.118.218495.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: